drug

ensartinib

1 story · latest Nov 6, 2026

Follow ensartinib. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Dec 2024 · NDA218171
Brand: Ensacove

Timeline

FDA approves ensartinib for ALK-positive locally advanced or metastatic NSCLC

Nov 6Regulatory decisionensartinib

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.